Taken together, the efficacy of inhibitors in increasing TSH-stimulated RAIU in the invasive fronts of thyroid cancer is most likely to be compromised by the presence of TGF-β in tumor microenvironment. This evidence concerns the gene TGFB1 and neoplasm.